Skip to main content
main-content

The independent medical news service

Prostate cancer

15-02-2019 | Prostate cancer | News | Article

Further support for [177Lu]-PSMA-617 in men with mCRPC

Results from an expansion cohort add support for the use of lutetium-177-prostate-specific membrane antigen-617 in heavily pretreated men with metastatic castration-resistant prostate cancer.

15-02-2019 | Prostate cancer | News | Article

Real-world data confirm better mCRPC OS with hormonal therapy in Black versus White men

An analysis of a US database shows that Black individuals who receive abiraterone acetate or enzalutamide for metastatic castration-resistant prostate cancer have better overall survival than their White counterparts.

14-02-2019 | Prostate cancer | News | Article

Long-term data support SBRT for low-, intermediate-risk prostate cancer

Stereotactic body radiotherapy has a favorable long-term disease control and safety profile in the setting of low- or intermediate-risk prostate cancer, say US researchers who analyzed individual patient data from over 2000 prospectively treated men.

12-02-2019 | Prostate cancer | News | Article

Conservative management of low-risk prostate cancer increasing in USA

US patients with low-risk localized prostate cancer are increasingly being managed with active surveillance or watchful waiting, finds a database analysis.

07-02-2019 | Prostate cancer | News | Article

Adding docetaxel to ADT for high-risk nonmetastatic prostate cancer questioned

Supplementing androgen deprivation therapy with docetaxel does not appear to improve the outcomes of men with high-risk nonmetastatic prostate cancer and rising prostate-specific antigen levels after treatment, indicate phase III trial findings.

04-02-2019 | Prostate cancer | News | Article

Time to prostate cancer surgery does not affect outcomes in higher-risk patients

Modest differences in the time from diagnosis to radical prostatectomy do not appear to affect the outcomes of men with high- or very-high-risk prostate cancer, say the authors of a chart review.

29-01-2019 | Prostate cancer | News | Article

GnRH agonists, orchiectomy linked to increased risk for non-Alzheimer’s dementia

A population-based study has not replicated the previously reported association between Alzheimer’s dementia and androgen deprivation therapy, but suggests that the risk for non-Alzheimer’s dementia may be elevated with use of gonadotropin-releasing hormone agonists and orchiectomy.

16-01-2019 | Prostate cancer | News | Article

Germline BRCA2 mutations impact mCRPC survival

Germline mutations in the BRCA2 gene, but not other DNA damage repair genes, are associated with poorer outcomes among patients with metastatic castration-resistant prostate cancer, study findings indicate.

04-01-2019 | Prostate cancer | News | Article

Microsatellite instability linked to immunotherapy response in prostate cancer patients

The presence of the microsatellite instability-high/mismatch repair-deficient phenotype could help select advanced prostate cancer patients who are likely to derive durable clinical benefit from treatment with checkpoint inhibitors, say researchers.

02-01-2019 | Prostate cancer | News | Article

Intermediate-term androgen suppression benefits higher risk prostate cancer

Patients treated with 18 months of androgen suppression plus radiotherapy have a significantly lower rate of prostate cancer-specific death at 10 years than those who receive 6 months of androgen suppression and radiotherapy, researchers report.

20-12-2018 | Prostate cancer | News | Article

Radical prostatectomy linked to long-term survival gains

Men with localised prostate cancer derive long-term survival benefits from radical prostatectomy relative to watchful waiting, indicate the 29-year follow-up results of the SPCG-4 trial.

28-11-2018 | Oncology | News | Article

Multiparametric MRI does not render systematic prostate biopsy obsolete

Pre-biopsy multiparametric magnetic resonance imaging improves the detection of clinically significant prostate cancer in biopsy-naive patients but does not appear to remove the need for systematic biopsy, MRI-FIRST study data show.

22-11-2018 | Oncology | Main feed | News

Boosted surgical approach can match radiotherapy for prostate cancer survival

Treatment with radical prostatectomy plus adjuvant external beam radiotherapy and androgen deprivation therapy can offer equivalent survival outcomes to a nonsurgical approach in patients with high-risk prostate cancer, research shows.

09-11-2018 | Prostate cancer | News | Article

Prostate cancer patients willing to make trade-offs between survival, side effects

Men with a new diagnosis of nonmetastatic prostate cancer say they would accept small reductions in survival odds if that meant fewer side effects and an improved quality of life, suggests the COMPARE study.

06-11-2018 | Oncology | Main feed | News

Run-in period may improve adherence to aspirin for chemoprevention

In patients undergoing radical therapy for cancer, an 8-week run-in period of aspirin is acceptable and well tolerated, and could reduce the risk for nonadherence and participant attrition in adjuvant and prevention trials, say researchers.

02-11-2018 | Prostate cancer | News | Article

STAMPEDE suggests radiation OS benefit for select metastatic prostate cancer patients

The latest results from the STAMPEDE trial do not show an additional overall survival benefit with radiotherapy for men undergoing androgen deprivation therapy with or without docetaxel for newly diagnosed metastatic prostate cancer.

25-10-2018 | Oncology | News | Article

LHRH therapy may be SPAREd for abiraterone-treated mCRPC patients

Men with metastatic castration-resistant prostate cancer who are beginning treatment with abiraterone acetate plus prednisone may not need luteinizing hormone-releasing hormone therapy, suggest exploratory findings presented at the ESMO 2018 Congress in Munich, Germany.

18-10-2018 | Oncology | Main feed | News

Long-term PFS benefits of pelvic irradiation shown in prostate cancer

An updated analysis of the NRG/RTOG 9413 trial shows that the benefits of whole pelvic radiotherapy plus neoadjuvant hormonal therapy persist in the long term in patients with intermediate- or high-risk localised prostate cancer.

14-09-2018 | Prostate cancer | News | Article

Meta-analysis consolidates evidence against PSA-based screening

Prostate-specific antigen-based screening may lead to a modest reduction in prostate cancer-specific mortality but has no effect on overall survival, say the authors of a meta-analysis published in The BMJ.

13-09-2018 | Prostate cancer | News | Article

HRQoL unaffected by addition of apalutamide to androgen deprivation therapy

The addition of apalutamide to androgen deprivation therapy has no detrimental effect on health-related quality of life in men with nonmetastatic castration-resistant prostate cancer, an analysis of data from the SPARTAN trial shows.

image credits